Zinc Sulfate
drug drugOn this page
Also known as NSC-135806NSC-32677PennineSootheyeSulfuric acid, zinc salt (1:1)White vitriolZ spanZinc (as sulfate)Zinc (as sulphate)Zinc sulfate (1:1) heptahydrateZinc sulfate (1:1) monohydrateZinc sulfate (anhydrous)Zinc sulfate anhydrousZinc sulfate component of multrysZinc sulfate component of tralementZinc sulfate hydrateZinc sulfate monohydrateanhydrousunspecified
Summary
Zinc Sulfate (CHEMBL1200929) is an approved small molecule (ATC A12CB01); indicated across 16 conditions including anemia and iron deficiency anemia.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: A12CB01 (+1 more)
- Indications: 16 conditions
- Clinical trials: 54
- Chemistry: 161.4 Da · O4SZn
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1200929 |
| Name | Zinc Sulfate |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 24424 |
| ChEBI | CHEBI:35176 |
| ATC | A12CB01, B05XA18 |
| Molecular formula | O4SZn |
| Molecular weight | 161.4 |
| InChIKey | NWONKYPBYAMBJT-UHFFFAOYSA-L |
SMILES: [O-]S(=O)(=O)[O-].[Zn+2]
IUPAC name: zinc sulfate
ChEBI definition: A metal sulfate compound having zinc(2+) as the counterion.
Other ChEBI roles (chemical / environmental): fertilizer.
Also known as: NSC-135806, NSC-32677, Pennine, Sootheye, Sulfuric acid, zinc salt (1:1), White vitriol, Z span, Zinc (as sulfate), Zinc (as sulphate), Zinc sulfate, Zinc sulfate (1:1) heptahydrate, Zinc sulfate (1:1) monohydrate
Patent coverage: 82,374 distinct patent families (154,994 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
2 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).
| Indication | Phase | MONDO | EFO |
|---|---|---|---|
| anemia | 4 | MONDO:0002280 | EFO:0004272 |
| iron deficiency anemia | 4 | MONDO:0001356 | HP:0001891 |
10 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.
| Disease (in trials) | Phase | MONDO | EFO |
|---|---|---|---|
| pneumonia | 3 | MONDO:0005249 | EFO:0003106 |
| bronchiolitis | 3 | MONDO:0002465 | HP:0011950 |
| obesity disorder | 2 | MONDO:0011122 | EFO:0001073 |
| chronic kidney disease | 2 | MONDO:0005300 | EFO:0003884 |
| canker sore | 2 | MONDO:0005318 | EFO:0003938 |
| alcoholic hepatitis | 2 | MONDO:0001505 | EFO:1001345 |
| mucositis | 2 | MONDO:0020579 | EFO:1001898 |
| diarrheal disease | 2 | MONDO:0001673 | HP:0002014 |
| sickle cell disease | 2 | MONDO:0011382 | MONDO:0011382 |
| hyperlipidemia | 2 | MONDO:0021187 | MONDO:0021187 |
3 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 54.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 18 |
| PHASE2 | 9 |
| PHASE4 | 8 |
| PHASE2/PHASE3 | 8 |
| PHASE3 | 7 |
| PHASE1/PHASE2 | 2 |
| PHASE1 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06517862 | PHASE4 | RECRUITING | Efficacy & Safety of Oral Adjuvants to Phototherapy in Neonatal Hyperbilirubinemia |
| NCT00459485 | PHASE4 | COMPLETED | Effects of Initiation and Discontinuation of Short Term Zinc Supplementation on Plasma Zinc Concentration |
| NCT01571856 | PHASE4 | COMPLETED | Efficacy of Use of Zinc in the Treatment of Acute Diarrhea in Infants |
| NCT03098810 | PHASE4 | UNKNOWN | Effect of Zinc Supplementation on Appetite and Growth in Primary Malnourished Children |
| NCT03117192 | PHASE4 | COMPLETED | Zinc Supplementation on Cellular Immunity in Thalassemia Major |
| NCT04050488 | PHASE4 | UNKNOWN | Zinc Supplementation on Very Low Birth Weight Infant |
| NCT04370782 | PHASE4 | COMPLETED | Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting |
| NCT05311540 | PHASE4 | COMPLETED | Zinc Supplementation In Very Low Birth Weight Infants-A Randomised Controlled Trial |
| NCT06433674 | PHASE3 | NOT_YET_RECRUITING | Enteral Zinc Supplementation in Very Low Birth Weight Infants |
| NCT07275827 | PHASE3 | NOT_YET_RECRUITING | Comparative Study Evaluating Safety and Effectiveness of ( Proton Pump Inhibitor Versus Vonoprazan ) Based Triple Therapy With or Without Zinc to Eradicate H. Pylori Infection |
| NCT00036881 | PHASE3 | COMPLETED | Zinc Sulfate in Preventing Loss of Sense of Taste in Patients Undergoing Radiation Therapy for Head and Neck Cancer |
| NCT00142285 | PHASE3 | COMPLETED | Zinc Pneumonia Outpatient Trial in Children < 2 Years |
| NCT00355043 | PHASE3 | COMPLETED | Efficacy of Zinc in the Treatment of Bronchiolitis and Prevention of Wheezing Respiratory Illness in Children Less Than Two Years Old |
| NCT00370968 | PHASE2/PHASE3 | COMPLETED | Zinc-ORS in Severe and Complicated Acute Diarrhea |
| NCT01015183 | PHASE2/PHASE3 | COMPLETED | Prevention Chemotherapy Induced Mucositis by Zinc Sulfate |
| NCT01166815 | PHASE2/PHASE3 | COMPLETED | Zinc Supplementation to Reduce Diarrhea Rates in Adults in Western Kenya. |
| NCT01737086 | PHASE2/PHASE3 | TERMINATED | Comparing the Efficacy of Two Oral Rehydration Solutions, With or Without the Probiotic Lactobacillus Reuteri DSM 17938 and Zinc, on the Duration and Severity of Acute Gastroenteritis in 6 - 36 Months Old Children in Out-patient Care |
| NCT01809132 | PHASE2/PHASE3 | COMPLETED | Efficacy Study of Anakinra, Pentoxifylline, and Zinc Compared to Methylprednisolone in Severe Acute Alcoholic Hepatitis |
| NCT02516475 | PHASE2/PHASE3 | COMPLETED | Effects of Zinc Supplementation on Anthropometric Factors, Apelin and Inflammatory Markers in Obese Individuals |
| NCT03158168 | PHASE3 | UNKNOWN | Intralesional Candidal Antigen Versus Intralesional Zinc Sulphate in Treatment of Cutaneous Warts |
| NCT04301336 | PHASE2/PHASE3 | COMPLETED | Different Treatment Modalities in the Management of the Painful Crisis in Pediatric Sickle- Cell Anemia |
| NCT06561061 | PHASE2/PHASE3 | COMPLETED | Zinc for Infection Prevention in Sickle Cell Anemia-2 (ZIPS-2) |
| NCT06869798 | PHASE3 | COMPLETED | EFFECTIVENESS OF ZINC AS AN ADJUVANT TO STANDARD THERAPY VERSUS STANDARD THERAPY ALONE IN CHILDREN |
| NCT07102836 | PHASE2 | RECRUITING | COMPARISON OF ZINC AND PROBIOTICS ON NEONATES WITH INDIRECT HYPERBILIRUBINEMIA UNDERGOING PHOTOTHERAPY |
| NCT01019083 | PHASE1/PHASE2 | COMPLETED | Studies of Immune Responses to Orally Administered Vaccines in Developing Country |
| NCT01062009 | PHASE1/PHASE2 | COMPLETED | Safety and Dose Escalation Study of Zinc Supplementation in Critically Ill Children |
| NCT01140074 | PHASE2 | UNKNOWN | Efficacy of Zinc Sulfate With Probiotics for the Treatment of Acute Diarrhea in Children |
| NCT01210014 | PHASE2 | COMPLETED | Systemic Zinc Sulphate in Treatment of Recurrent Aphthous Ulcerations:A Doubleblind, Placebo Controled Study |
| NCT02217189 | PHASE2 | COMPLETED | Study of the Effect of Oral Zinc Supplementation on Superoxide Radical Scavengers |
| NCT02335593 | PHASE2 | COMPLETED | Efficacy Study of Zinc Supplementation on Anemia, Oxidative Stress and Inflammation in Hemodialysis Patients |
| NCT02985905 | PHASE2 | COMPLETED | The Effect of Oral Zinc Supplementation on Thiol Oxido-reductive Index |
| NCT05366595 | PHASE2 | COMPLETED | Zinc Supplementation in Pediatric Sepsis |
| NCT05395143 | PHASE2 | UNKNOWN | Study to Assess the Effect of Zinc in Atorvastatin Treated Hyperlipidemic Patients |
| NCT06482034 | PHASE2 | COMPLETED | Effect of N-acetyl Cysteine and Zinc in Management of Head and Neck Cancer Radiotherapy Induced Oral Mucositis |
| NCT01162109 | PHASE1 | ACTIVE_NOT_RECRUITING | Zinc Therapy in Critical Illness |
| NCT03690583 | PHASE1 | COMPLETED | Immunomodulation by Zinc Supplementation in Children With Pneumonia |
| NCT00395226 | Not specified | TERMINATED | Zinc Sulfate in the Treatment of Rosacea: A Randomized, Controlled Trial |
| NCT00513929 | Not specified | UNKNOWN | Zinc as Adjunct to Treatment of Pneumonia |
| NCT00682955 | Not specified | COMPLETED | Comparing the Efficacy of Different Zinc Formulations in the Treatment of Diarrhea |
| NCT01198587 | Not specified | COMPLETED | Oral Zinc for the Treatment of Acute Diarrhea in US Children |
| NCT01229579 | Not specified | COMPLETED | Effect of Zinc Supplementation on Response to Oral Polio Vaccine in Infants in Pakistan |
| NCT01612403 | Not specified | COMPLETED | Study the Effect of Oral Zinc Supplementation on High Molecular Weight Zinc Binding Protein in Semen |
| NCT01684059 | Not specified | COMPLETED | Study the Effect of Oral Zinc Supplementation on Enzymes of Nitric Oxide Pathway |
| NCT01892098 | Not specified | COMPLETED | Zinc and Bone Turnover Study in Adolescent Females |
| NCT02255942 | Not specified | COMPLETED | The Effect of Zinc on Iron Bioavailability From Fortified Extruded Rice Fortified With Ferric Pyrophosphate |
| NCT02714075 | Not specified | COMPLETED | Comparison of Iron Absorption From Extruded FePP-fortified Rice Containing Zinc, Citric Acid/Trisodium Citrate and EDTA |
| NCT03293641 | Not specified | COMPLETED | Zinc Supplementation in Children With Sickle Cell Disease in Western Kenya |
| NCT03361618 | Not specified | COMPLETED | Effect of Oral Zinc Sulfate Supplementation on Enzymes of Urate Pathway |
| NCT03404310 | Not specified | TERMINATED | Zinc Sulfate for Human Papillomavirus (HPV) |
| NCT03923829 | Not specified | UNKNOWN | The Effect of Zinc on the Gingival Crevicular Fluid Level of Total Oxidant Capacity in Type 2 Diabetic Patients |
| NCT04061538 | Not specified | COMPLETED | Efficiency and Safety of Zinc Sulphate to Reduce the Duration of Acute Diarrheal Disease Between 6 and 59 Months of Age |
| NCT05161611 | Not specified | COMPLETED | Effect of Oral Zinc Sulfate on Jaundice in Neonates Admitted to Neonatal Intensive Care Unit |
| NCT06556511 | Not specified | COMPLETED | Efficacy Of Zinc Towards The Outcome on Children With Sepsis |
| NCT07383363 | Not specified | COMPLETED | Comparison of Efficacy and Safety of Vita 6 Versus Zinc Along With Applied Behavioural Therapy |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Indicated for: anemia, iron deficiency anemia
- In clinical trials for: pneumonia, bronchiolitis, obesity disorder, chronic kidney disease, canker sore, alcoholic hepatitis, mucositis, diarrheal disease, sickle cell disease, hyperlipidemia